Business Strategy

Our business strategy is to commercialize pHLIP® technology by developing pHLIP® Drug Conjugates (PDCs) from our pipeline and by partnering with biopharmaceutical companies to enable or improve the safety and efficacy of their imaging agents, drugs or drug candidates.


Cybrexa Therapeutics holds exclusive worldwide development and commercialization rights to use pHLIP® peptides in the development of oncology therapeutics that include DNA damage repair inhibitors and cytotoxic molecules.


Intellectual Property

pHLIP, Inc. has exclusive rights to a comprehensive and growing IP portfolio built by the team of Dr. Ingrid A. Beattie, a member at Mintz Levin.


Integral to our business strategy is proliferation of our technology via multiple partnering and out-licensing in other fields and indications: Please contact us